{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:37:53Z","timestamp":1767926273916,"version":"3.49.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,15]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Osteoarthritis (OA) is a prevalent joint disease affecting the spine, hands, hips, knees, and feet. However, definitive drugs for OA are lacking, and current treatments are limited owing to inconvenient administration, inadequate functional improvement, and long-term side effects including gastrointestinal and cardiovascular adverse events. Therefore, in this study, we aimed to assess the pharmacokinetics and safety profiles of PK101, a fixed-dose combination (FDC) comprising PG201, a 12-herb extract used in OA treatment in traditional East Asian medicine, and celecoxib, a selective cyclooxygenase-2 inhibitor, by comparing its administration as an FDC and the corresponding individual formulations in healthy subjects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and methods:<\/jats:title>\n            <jats:p>A randomized, open-label, single-dose, 2\u2005\u00d7\u20052 crossover design with a cohort of healthy participants. All subjects received a single FDC tablet (405.4\u2005mg\u2005PG201 and 100\u2005mg celecoxib) or the individual formulations, with 7-day washout period between administrations. The estimation of maximum plasma concentration and area under the plasma concentration\u2013time curve from time zero to the time of the last quantifiable concentration of celecoxib involved determining the geometric mean ratios and 90% confidence intervals of the FDC compared to its individual formulations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Forty-six participants were enrolled; however, only 44 completed the study. The geometric mean ratios (90% confidence intervals) for the area under the plasma concentration\u2013time curve from time zero to the time of the last quantifiable concentration and maximum plasma concentration of celecoxib were 1.1124 (1.0601\u20131.1672) and 1.2788 (1.1708\u20131.3969), respectively. The time of maximum plasma concentration range was 1.0 to 4.0\u2005hours and 1.0 to 6.0\u2005hours (minimum\u2013maximum) for the FDC and individual formulations, respectively. Seven adverse events occurred in 6 subjects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The systemic exposure and safety profiles of the individual and FDC formulations were similar, supporting their potential as an innovative and effective therapeutic approach for OA treatment. All relevant data are within the paper and its Supporting Information files.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040494","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:04:09Z","timestamp":1732032249000},"page":"e40494","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of a fixed-dose combination of Celecoxib\/PG201 [Layla\u00ae] versus co-administration of individual formulations in healthy participants: A randomized trial"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3952-5096","authenticated-orcid":false,"given":"Ji Hye","family":"Song","sequence":"first","affiliation":[{"name":"Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea"},{"name":"Department of Medical Science, Chungnam National University College of Medicine, Daejeon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunsook","family":"Koh","sequence":"additional","affiliation":[{"name":"PMG Pharm Co., Ltd., Gyeonggi-do, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Young","family":"Moon","sequence":"additional","affiliation":[{"name":"PMG Pharm Co., Ltd., Gyeonggi-do, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Gyu","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jang Hee","family":"Hong","sequence":"additional","affiliation":[{"name":"Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea"},{"name":"Department of Medical Science, Chungnam National University College of Medicine, Daejeon, Republic of Korea"},{"name":"Department of Pharmacology, Chungnam National University College of Medicine, Daejeon, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8801-0323","authenticated-orcid":false,"given":"Jung","family":"Sunwoo","sequence":"additional","affiliation":[{"name":"Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.joca.2018.09.016","article-title":"Models of osteoarthritis: the good, the bad and the promising.","volume":"27","author":"Cope","year":"2019","journal-title":"Osteoarthritis Cartilage"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.15585\/mmwr.mm7241a1","article-title":"Prevalence of diagnosed arthritis - United States, 2019-2021.","volume":"72","author":"Fallon","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.semarthrit.2016.07.013","article-title":"The burden of musculoskeletal diseases in the United States.","volume":"46","author":"Yelin","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.3390\/ijms22041742","article-title":"Overview of MMP-13 as a promising target for the treatment of osteoarthritis.","volume":"22","author":"Hu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R6-20250504","first-page":"237","article-title":"The role of cytokines in osteoarthritis pathophysiology.","volume":"39","author":"Fernandes","year":"2002","journal-title":"Biorheology"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00296-014-2964-8","article-title":"Efficacy and safety of PG201 (Layla(\u00ae) and celecoxib in the treatment of symptomatic knee osteoarthritis: a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study.","volume":"34","author":"Yoo","year":"2014","journal-title":"Rheumatol Int"},{"key":"R9-20250504","first-page":"305","article-title":"The acceleration of articular cartilage degeneration in osteoarthritis by nonsteroidal anti-inflammatory drugs.","volume":"2","author":"Hauser","year":"2010","journal-title":"J Prolother"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.joca.2018.05.021","article-title":"Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review.","volume":"26","author":"Nakata","year":"2018","journal-title":"Osteoarthritis Cartilage"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40122-021-00260-1","article-title":"Management of osteoarthritis: expert opinion on NSAIDs.","volume":"10","author":"Magni","year":"2021","journal-title":"Pain Ther"},{"key":"R12-20250504","first-page":"CD002947","article-title":"Oral herbal therapies for treating osteoarthritis.","volume":"2014","author":"Cameron","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/ptr.3007","article-title":"Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part I: osteoarthritis.","volume":"23","author":"Cameron","year":"2009","journal-title":"Phytother Res"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4078\/jrd.2023.0084","article-title":"Medical treatment of osteoarthritis: botanical pharmacologic aspect.","volume":"31","author":"Park","year":"2024","journal-title":"J Rheum Dis"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jep.2016.01.029","article-title":"Prospective, randomized, double-blinded, double-dummy and multicenter phase IV clinical study comparing the efficacy and safety of PG201 (Layla) and SKI306X in patients with osteoarthritis.","volume":"181","author":"Ha","year":"2016","journal-title":"J Ethnopharmacol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12272-015-0654-z","article-title":"Constituents of PG201 (Layla\u00ae), a multi-component phytopharmaceutical, with inhibitory activity on LPS-induced nitric oxide and prostaglandin E2 productions in macrophages.","volume":"39","author":"Kim","year":"2016","journal-title":"Arch Pharm Res"},{"key":"R17-20250504","first-page":"81","article-title":"Efficacy and safety of celecoxib compared with placebo and etodolac for acute postoperative pain: a multicenter, double-blind, randomized, parallel-group, controlled trial.","volume":"77","author":"Ishiguro","year":"2015","journal-title":"Nagoya J Med Sci"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"595273","DOI":"10.1155\/2015\/595273","article-title":"Study of osteoarthritis treatment with anti-inflammatory drugs: cyclooxygenase-2 inhibitor and steroids.","volume":"2015","author":"Cho","year":"2015","journal-title":"Biomed Res Int"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.apsusc.2017.06.010","article-title":"Enhanced release and drug delivery of celecoxib into physiological environment by the different types of nanoscale vehicles.","volume":"422","author":"Khazraei","year":"2017","journal-title":"Appl Surf Sci"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cpt.1672","article-title":"Evaluating the role of solubility in oral absorption of poorly water-soluble drugs using physiologically-based pharmacokinetic modeling.","volume":"107","author":"Fink","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"R21-20250504","first-page":"50","article-title":"Interactions between traditional Chinese medicines and Western therapeutics.","volume":"13","author":"Chan","year":"2010","journal-title":"Curr Opin Drug Discov Dev"},{"key":"R22-20250504","first-page":"e37080","article-title":"Effects of non-steroidal anti-inflammatory drugs (NSAIDs) and gastroprotective NSAIDs on the gastrointestinal tract: a narrative review.","volume":"15","author":"Sohail","year":"2023","journal-title":"Cureus"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:03:09Z","timestamp":1746320589000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":20,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040494","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}